Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) fell 5.9% during trading on Tuesday . The company traded as low as $7.22 and last traded at $7.16. 51,687 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 129,657 shares. The stock had previously closed at $7.61.
Gyre Therapeutics Price Performance
The stock has a market capitalization of $671.32 million, a PE ratio of 358.18 and a beta of 1.72. The business has a 50 day moving average price of $8.76 and a 200 day moving average price of $9.70.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported $0.03 earnings per share for the quarter, meeting analysts' consensus estimates of $0.03. The company had revenue of $22.06 million for the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a return on equity of 9.73% and a net margin of 7.20%.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in GYRE. Barclays PLC grew its stake in Gyre Therapeutics by 13.5% during the 4th quarter. Barclays PLC now owns 10,543 shares of the company's stock valued at $128,000 after purchasing an additional 1,255 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Gyre Therapeutics by 15,083.3% during the first quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock valued at $140,000 after acquiring an additional 1,810 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after acquiring an additional 913 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Gyre Therapeutics by 11.1% in the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock valued at $168,000 after purchasing an additional 1,389 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Gyre Therapeutics by 9.1% during the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock worth $1,251,000 after acquiring an additional 8,624 shares during the last quarter. 23.99% of the stock is owned by institutional investors.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
